In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CAR-T Cancer Drugs Front And Center At ARM Investor Day

Executive Summary

Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.

You may also be interested in...

Keeping Track: Oncology Filings Galore In Run-Up To ASCO Meeting

The latest cancer drug development news and highlights from our FDA Performance Tracker.

Too Sick For CAR-T? Kite Reports Cerebral Edema Death

Kite Pharma investors were spooked on May 8 when the company revealed that an extremely ill patient died from cerebral edema related to its lead CAR-T candidate – the same severe side effect that derailed Juno's competing cell therapy.

CAR T-Cells, Helping US Firms & An “Ambitious” Plan For Advanced Therapies In The EU

As companies like Novartis, bluebird bio and Kite Pharma press on with developing cancer treatments based on cutting edge CAR T-cell technology, the new chair of the European Medicines Agency’s Committee for Advanced Therapies, Martina Schüssler-Lenz, tells the Pink Sheet about plans to help makers of these and other innovative advanced therapies.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts